← 홈

전체 프로그램

ADC 1032 · Antibody 4684 · CGT 2713 · 다음 갱신 D-13 · 마지막 7월 31일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,531개
CGTBiologicstaleEden BioCell Ltd.Phase 1

RPM CD19-mbIL15-CAR-T cells (RPM CD19-mbIL15-CAR-T cells)

B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma, Relapsed · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 DISCONTINUED
AntibodystaleAssociazione Volontari Pazienti…Phase 3

RT+CETUXIMAB (RT+CETUXIMAB)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
CGTBiologicstaleArtielle ImmunoTherapeuticsPhase 1

recombinant T cell receptor ligand (RTL1000, RTL1000 (recombinant T cell receptor ligand))

Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Chronic Progressive

#MultipleSclerosisChronicProgress#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 2%임상시험 1상태 ACTIVE
AntibodystaleEli Lilly and CompanyPhase 1

IMC-1121B (Ramucirumab, Ramucirumab (IMC-1121B))

Colorectal Carcinoma · Colorectal Carcinoma

#ColorectalCarcinoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJiangsu HengRui Medicine Co., L…Phase 3

Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan (Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleEli Lilly and CompanyPhase 2

Ramucirumab DP (Ramucirumab DP)

Carcinoma of Urinary Tract; Urethral Carcinoma · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#항체#면역항체+3
효능 ORR 28.8%임상시험 1상태 ACTIVE
AntibodystaleImugene LimitedPhase 2

Ramucirumab plus Paclitaxel (Ramucirumab plus Paclitaxel)

Gastric Cancer; Cancer of Stomach · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

Recombinant Human Interleukin-2 and Rituximab (Recombinant Human Interleukin-2 and Rituximab)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleZhejiang Cancer HospitalPhase 2

Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)

Uterine Cervical Neoplasms; Oncolytic Virotherapy · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
ADCBiologicstaleXijing HospitalPhase 2

RC48-ADC (Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent, Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC))

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 ACTIVE
CGTBiologicstaleThe Affiliated Hospital of Xuzh…Phase 1

Recombinant oncolytic adenovirus injection solution of VT-101 (Recombinant oncolytic adenovirus injection solution of VT-101)

Non-muscle Invasive Bladder Cancer · Non-muscle Invasive Bladder Cancer

#Non-muscleInvasiveBladderCancer#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleLiang PengPhase 1

Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib (Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib)

Advanced/Metastatic Hepatocellular Carcinoma · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleDonghua ZhangPreclinical

Recurrent/refractory multiple myeloma (Recurrent/refractory multiple myeloma, Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells, r/r MM)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleTianjin Medical University Canc…Phase 2

Regorafenib and tislelizumab (Regorafenib and tislelizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAsan Medical CenterPhase 2

nivolumab (Opdivo, Regorafenib/Nivolumab)

Carcinoma, Hepatocellular; Hepatoma · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#Antibody#Phase2#항체#면역항체+5
효능 ORR 42%임상시험 1상태 ACTIVE
AntibodystaleWashington University School of…Phase 1

Relatilmab (Relatilmab)

Advanced Melanoma; Metastatic Melanoma · Advanced Melanoma

#AdvancedMelanoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Relatlimab FDC + Nivolumab)

Metastatic Triple-negative Breast Cancer · Metastatic Triple-negative Breast Cancer

#MetastaticTriple-negativeBreastC#Antibody#Phase2#항체#면역항체+2
효능 ORR 61.9%임상시험 1상태 RECRUITING
AntibodystaleLoyola UniversityPhase 2

infliximab (Remicaide, Remicaide (infliximab))

Toxic Epidermal Necrolysis · Toxic Epidermal Necrolysis

#ToxicEpidermalNecrolysis#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleTevaPreclinical

Reslizumab (Reslizumab)

Asthma · Asthma

#Asthma#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleUniversity of Alabama at Birmin…Phase 1

Retifanlimab, INCAGN02385, INCAGN02390 (Retifanlimab, INCAGN02385, INCAGN02390)

Diffuse Large B Cell Lymphoma; Lymphoma, B-Cell · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase1#항체#면역항체+4
효능 ORR 100%임상시험 1상태 DISCONTINUED

147 / 177 페이지

← 이전다음 →